Psyence Biomedical Ltd. (PBM)
Automate Your Wheel Strategy on PBM
With Tiblio's Option Bot, you can configure your own wheel strategy including PBM - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol PBM
- Rev/Share 0.0
- Book/Share 8.01
- PB 0.3121
- Debt/Equity 0.0
- CurrentRatio 8.09
- ROIC -0.2244
- MktCap 47548.0
- FreeCF/Share 0.0
- PFCF 0.0
- PE -6.0542
- Debt/Assets 0.0
- DivYield 0
- ROE -0.1153
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 5
- P/B Score 3
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Psyence BioMed Announces Exercise of Put Option by PsyLabs and Strategic Equity Investment
Published: February 20, 2026 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced that Psyence Labs Ltd., a leading developer and manufacturer of pharmaceutical-grade psychedelic compounds ("PsyLabs") has exercised its rights under a previously disclosed put option agreement (the "Put Option Agreement"), pursuant to which Psyence BioMed will make an equity investment in PsyLabs at a fair market value determined in accordance with the terms of the Put Option Agreement.
Read More
Psyence BioMed Announces Results of Annual and Special Meeting of Shareholders
Published: February 17, 2026 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced the voting results from its Annual and Special Meeting of Shareholders (the “Meeting”), held at 9:00 a.m. Eastern Time on February 12, 2026. Shareholders voted in favour of all matters of business presented at the Meeting, including the election of directors, the appointment of auditors and the approval of share consolidation authority for the board of directors (the “Board”).
Read More
Psyence BioMed Announces Settlement of Shareholder Litigation
Published: February 11, 2026 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence BioMed" or the "Company") today announced that it has entered into a settlement agreement to resolve a direct shareholder claim made by KAOS Capital Ltd ("KAOS"). The claim, originally made on January 14, 2026, and amplified on January 26, 2026, alleged, among other things, improper and oppressive actions on the part of the Company against KAOS, resulting in KAOS suffering alleged damages (the "KAOS Allegations"). The Company, its board of directors ("Board") and officers have denied the allegations and believe they are unsubstantiated and meritless.
Read More
Psyence BioMed Announces Adjournment of Annual and Special Shareholder Meeting on January 22, 2026
Published: January 22, 2026 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”) today announced that it adjourned its annual and special meeting of shareholders (the “Meeting”) until February 12, 2026.
Read More
Psyence BioMed Achieves Milestone in Natural Ibogaine HCl Production and Strengthens Balance Sheet With No Debt and $12m Cash
Published: January 05, 2026 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced a significant scientific and manufacturing achievement.
Read More
Psyence BioMed Announces Effective Date for 1-for-7.97 Reverse Stock Split
Published: May 01, 2025 by: Newsfile Corp
Sentiment: Neutral
New York, New York--(Newsfile Corp. - May 1, 2025) - Psyence Biomedical Ltd. (NASDAQ: PBM) ("Psyence BioMed" or the "Company") today announced the effective date of its 1-for-7.97 share consolidation (reverse stock split) of the Company's issued and outstanding common shares.
Read More
Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, names Albert P. Garcia-Romeu, Ph.D.
Published: March 10, 2025 by: GlobeNewsWire
Sentiment: Neutral
TORONTO, March 10, 2025 (GLOBE NEWSWIRE) -- Psyence Group Inc ("Psyence Group" or the "Company") (CSE: PSYG) is pleased that its NASDAQ-listed associate, Psyence Biomedical Ltd (NASDAQ: PBM) ("PBM" or "Psyence Biomed"), has announced that it will work closely with Albert P. Garcia-Romeu, Ph.D.
Read More
Psyence Biomed Names Albert P. Garcia-Romeu, Ph.D.
Published: February 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced that it will work closely with Albert P.
Read More
About Psyence Biomedical Ltd. (PBM)
- IPO Date 2021-12-10
- Website https://www.psyencebiomed.com
- Industry Biotechnology
- CEO Jody Aufrichtig
- Employees 12